IRadimed Corporation — Q1 2022 Form 10-Q
Business and period: Unaudited results for the three months ended March 31, 2022, compared with Q1 2021. IRadimed develops, manufactures, and sells MRI-compatible infusion pumps, patient-monitoring systems, accessories, disposables, and services to hospitals and acute-care facilities.
Financial performance
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $12.31 million | $9.22 million | +33.5% |
| Gross profit / margin | $9.38 million / 76.2% | $7.06 million / 76.6% | Profit +32.8%; margin -0.4 percentage points |
| Operating expenses | $6.30 million | $5.29 million | +19.3% |
| Operating income / margin | $3.07 million / 25.0% | $1.78 million / 19.3% | Income +73.0% |
| Net income | $2.49 million | $1.39 million | +79.3% |
| Diluted EPS | $0.20 | $0.11 | Up $0.09 |
| Operating cash flow | $1.43 million | $0.94 million | Up $0.48 million |
Revenue mix: U.S. revenue rose 37.2% to $9.98 million; international revenue rose 19.5% to $2.33 million. Patient vital-sign monitoring system revenue nearly doubled, up 99.5% to $5.19 million. Infusion-pump revenue fell 6.3% to $3.28 million. Disposables, services, and other revenue increased 25.9% to $3.32 million. Device sales growth was supported by higher monitoring-system sales and selling prices.
Cash, liquidity, and obligations: Cash and cash equivalents were $50.45 million and investments were $0.50 million at March 31, 2022, down from a combined $62.50 million at year-end. Working capital was $59.3 million, versus $69.4 million at December 31, 2021. The decline primarily reflects a $12.56 million special dividend paid during the quarter. Investing cash outflow was $0.42 million; financing cash outflow was $12.55 million. No borrowings are reported; liabilities include operating lease obligations of $2.41 million, of which $0.28 million is current. Management expects existing cash, investments, and operating cash generation to fund requirements for at least 12 months.
Changes, outlook, and risks
- Revenue growth outpaced expense growth, improving operating and net margins. Gross margin edged down because of unfavorable labor and overhead costs, partly offset by favorable geographic sales mix.
- Sales and marketing expense increased 29.0%, primarily from higher commissions, sales activity, payroll, and benefits. General and administrative expense increased 11.8%; research and development expense was broadly unchanged.
- Management expects higher revenue for the remainder of 2022 than in the comparable 2021 period, driven by medical devices, accessories, disposables, and services. It also expects higher operating expenses, particularly sales and marketing and general and administrative expenses. Expected full-year 2022 effective tax rate is approximately 23%.
- Key risks include FDA and other regulatory clearances and inspections, reliance on a limited product range, sole-sourced critical components, supply-chain disruption, COVID-19-related uncertainty, competitive and customer cost pressures, and product liability or recall exposure. A 10% change in the U.S. dollar against the yen was expected to have an immaterial net-income effect; a 100-basis-point interest-rate change was expected to have an immaterial investment fair-value effect.
- Purchase orders totaled $5.53 million and were not recognized as balance-sheet liabilities. The company had approximately $138,000 accrued for various legal matters; management stated known matters were not expected to materially affect results or financial position. The principal facility is leased from an entity controlled by CEO Roger Susi; 2021 rent paid was $461,874. No material off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective, with no material change in internal controls reported.
Important facts for investors to verify
- Whether the monitoring-system sales surge and higher selling prices are sustainable, given the decline in infusion-pump revenue.
- Whether labor and overhead pressures, operating-expense growth, and COVID-19-related hospital purchasing delays affect the outlook and margins.
- Cash-generation and liquidity after the special dividend, including ongoing capital needs and the company’s stated 12-month liquidity outlook.
- Exposure to sole-sourced components and regulatory actions, as well as the terms and governance of the related-party facility lease.
- Future developments in legal matters and purchase commitments; the filing does not quantify a clear potential loss beyond the accrued amount.